Fujimoto Takashi, Yoshimatsu Kazuhiko, Yokomizo Hajime, Umehara Arihiro, Watanabe Kiyo, Otani Taisuke, Matsumoto Atsuo, Osawa Gakuji, Itagaki Hiroko, Ogawa Kenji
Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
Gan To Kagaku Ryoho. 2008 Nov;35(12):2274-6.
Bevacizumab, a humanized monoclonal antibody to VEGF for advanced recurrent colorectal cancer, has been known for complications of gastrointestinal perforation, hemorrhage, thromboembolism and proteinuria, as adverse effects. These findings must be taken care as well as adverse drug reactions (ADR) caused by combination chemotherapy. We here in present a clinical experience in treatment with bevacizumab for unresectable colorectal cancer. Six patients treated with bevacizumab for over two courses until April 2008 were analyzed for this study. PR was obtained in one case with mFOLFOX6. Even though, grade 3 neutropenia was observed in only one case with FOLFIRI, the other cases had grade 2 or less in ADR. In addition, there were no any specific ADRs related with bevacizumab, so we concluded that combination chemotherapy for advanced recurrent colorectal cancer with bevacizumab was well-tolerated.
